Corporate Profile

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to develop best-in-class molecules for the treatment of liver and viral diseases to improve patient outcomes. Aligos applies its chemistry-centric approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses. For more information visit www.Aligos.com or follow us on LinkedIn.